Clay Siegall is the CEO of the Seattle-based biotech firm, Seattle Genetics. His company specializes in developing targeted therapy drugs for diseases that have not had considerable mortality improvements in years. Siegall is a proud alumnus of the revered University of Maryland where he graduated with a BS in zoology. He also holds a PhD in genetics from the world-renowned George Washington University.
After incorporating Seattle Genetics in 1998, Siegall has guided the company to ranks as one of the leading companies in the targeted therapy industry. Under his leadership, Seattle Genetics developed the first FDA-approved antibody drug conjugate. Presently, it has several approved indications. The company is also developing a full-bodied pipeline of over 20 drugs besides engaging in some strategic partnerships with well-known drug manufacturers, including Genentech and Pfizer.
Under Siegall’s transformative leadership, Seattle Genetics has evolved from a small startup with a handful of researchers to an actual power player in the cancer research industry. Moreover, Siegall has impressive plans for Seattle Genetics. With an ever growing list of drugs being developed and number of potential indications, the company is well-positioned to engage in developing viable therapies for the 21st century.
He believes that conventional cancer treatment means like systematic chemotherapies will end up in the historic dustbin. As the efficacy and value of targeted therapies becomes apparent in years ahead, Siegall believes that the traditional therapies will be succeeded by the more tolerable and broadly effective targeted drugs.
About Clay Siegall
Clay Siegall co-established Seattle Genetics. He serves as the company’s chairman. Previously, Dr. Siegall worked for National Cancer Institute and the National Institute of Health. In addition, he rendered his services for Bristol-Myers Squibb Pharmaceutical Research Institute.
Dr. Clay Siegall has authored over 70 publications. Additionally, he holds more than 15 patents. He serves on the board of directors of Alder BioPharmaceuticals, a leading private biotechnology company. One of Dr. Siegall’s accomplishments is leading Seattle Genetics in developing anti-body cancer therapies like ADCETRIS. He has also guided the company’s capital raising activities. Through his efforts, Clay has helped Seattle Genetics to secure more than $675 million from private and public financing, including the firm’s Initial Public Offering (IPO) in 2001.